Science Translational Medicine

Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research. The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases. The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine. The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.

《Science Translational Medicine》是一本在线期刊，专注于交叉学科的科学、工程和医学研究成果。其旨在为不同学科的研究人员提供一个平台，促进其在生物医学、转化和临床研究方面的最新进展。该期刊致力于解决科学知识转化为有效治疗和健康措施缓慢的问题，填补临床前研究和医学应用之间的知识空白，加速将知识转化为预防、诊断和治疗人类疾病的新方法。 该期刊涵盖了广泛的领域，包括心血管疾病、免疫学/疫苗、代谢/糖尿病/肥胖、神经科学/神经病学/精神病学、癌症、传染病、政策、行为、生物工程、化学基因组学/药物发现、成像、医学纳米技术等。其目标读者包括学术界、政府、生物技术和制药行业的研究人员和管理人员，以及医学科学家、监管者、政策制定者、投资者、业务开发商和资助机构相关人员。